Global Information
회사소개 | 문의

종양괴사인자수용체 슈퍼패밀리 멤버 4(ACT35 항체/TAX 전사활성 당단백질 1 수용체/CD134/TNFRSF4) : 파이프라인 리뷰

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 08월 상품 코드 363119
페이지 정보 영문 71 Pages
가격
US $ 3,500 ₩ 4,018,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,036,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,054,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


종양괴사인자수용체 슈퍼패밀리 멤버 4(ACT35 항체/TAX 전사활성 당단백질 1 수용체/CD134/TNFRSF4) : 파이프라인 리뷰 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2018
발행일 : 2018년 08월 페이지 정보 : 영문 71 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

세계 각국에서의 종양괴사인자수용체 슈퍼패밀리 멤버 4(ACT35 항체/TAX 전사활성 당단백질 1 수용체/CD134/TNFRSF4) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시 최신 동향, 각 임상시험 단계 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

  • 서론
    • 분석 범위
  • 종양괴사인자수용체 슈퍼패밀리 멤버 4(ACT35 항체/TAX 전사활성 당단백질 1 수용체/CD134/TNFRSF4) 개요
  • 치료제 개발
    • 임상시험 단계별
    • 치료 분야별
    • 증상별
  • 파이프라인 제품 개요
    • 초기 단계 제품
  • 각 기업에서 개발중인 치료제
  • 치료제 평가
    • 단독치료 제품/병용 제품별
    • 작용기서별
    • 투여 방법별
    • 분자 종류별
  • 치료제 개발에 참여하고 있는 기업
    • Alligator Bioscience AB
    • Apogenix GmbH
    • BioInvent International AB
    • Bristol-Myers Squibb Company
    • Enumeral Biomedical Holdings, Inc.
    • Genentech, Inc.
    • GlaxoSmithKline Plc
    • MedImmune, LLC
    • Pfizer Inc.
  • 약제 개요
    • ADC-1015
      • 제품 개요
      • 작용기서
      • 연구 개발(R&D) 진전 상황
    • BMS-986178
    • Delta-24-RGDOX
    • durvalumab + MEDI-6383
    • GSK-3174998
    • MEDI-0562
    • MEDI-6383
    • Monoclonal Antibodies to Agonize OX40 for Oncology
    • Monoclonal Antibodies to Agonize OX40 for Oncology
    • PF-04518600
    • Recombinant Protein to Agonize OX40 for Solid Tumor
    • Recombinant Proteins to Agonize OX40 and Notch 3 for Type 1 Diabetes
    • RG-7888
  • 개발이 휴지 상태인 제품
  • 개발이 중지된 제품
  • 주목해야 할 최신 동향 및 프레스 릴리스(총 3건)
  • 부록

도표

KSM 16.07.27

List of Tables

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Indications, H2 2018
  • Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Products under Development by Companies, H2 2018 (Contd..2), H2 2018
  • Products under Development by Companies, H2 2018 (Contd..3), H2 2018
  • Number of Products under Investigation by Universities/Institutes, H2 2018
  • Products under Investigation by Universities/Institutes, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pipeline by AbbVie Inc, H2 2018
  • Pipeline by Abeome Corp, H2 2018
  • Pipeline by Alligator Bioscience AB, H2 2018
  • Pipeline by Apogenix AG, H2 2018
  • Pipeline by BioInvent International AB, H2 2018
  • Pipeline by Bristol-Myers Squibb Co, H2 2018
  • Pipeline by Denceptor Therapeutics Ltd, H2 2018
  • Pipeline by GigaGen Inc, H2 2018
  • Pipeline by GlaxoSmithKline Plc, H2 2018
  • Pipeline by Incyte Corp, H2 2018
  • Pipeline by Innovent Biologics Inc, H2 2018
  • Pipeline by Invenra Inc, H2 2018
  • Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018
  • Pipeline by MedImmune LLC, H2 2018
  • Pipeline by Pfizer Inc, H2 2018
  • Pipeline by Zai Lab Ltd, H2 2018
  • Dormant Projects, H2 2018
  • Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Top 10 Indications, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

영문목차

Summary:

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes.

The latest report Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response.

OX40 also plays a crucial role in both Th1 and Th2 mediated reactions. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 2, 5 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal, Infectious Disease and Metabolic Disorders which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Colorectal Cancer, Renal Cell Carcinoma, Atopic Dermatitis (Atopic Eczema), B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Cervical Cancer, Endometrial Cancer, Gastric Cancer, Graft Versus Host Disease (GVHD), Head And Neck Cancer, Hematological Tumor, Hepatitis B, Hypopharyngeal Cancer, Laryngeal Cancer, Metastatic Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
  • The report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Overview
    • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Abeome Corp
    • Alligator Bioscience AB
    • Apogenix AG
    • BioInvent International AB
    • Bristol-Myers Squibb Co
    • Denceptor Therapeutics Ltd
    • GigaGen Inc
    • GlaxoSmithKline Plc
    • Incyte Corp
    • Innovent Biologics Inc
    • Invenra Inc
    • Kyowa Hakko Kirin Co Ltd
    • MedImmune LLC
    • Pfizer Inc
    • Zai Lab Ltd
  • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drug Profiles
    • ABBV-368 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ABM-193 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATOR-1015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bispecific Monoclonal Antibodies to Agonize TNFRSF4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986178 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • durvalumab + tavolimab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fusion Protein to Agonize OX40 for Solid Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fusion Proteins to Agonize OX40 and NOTCH1 for Type 1 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-3174998 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HuOHX-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IBI-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCAGN-1949 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KHK-4083 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Agonize OX40 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Agonize OX40L Receptor for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target OX40L for Transplant Rejection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MSB-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OrthomAb - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-04518600 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCB-340 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tavolimab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tavolimab + tremelimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZL-1101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Dormant Products
  • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Discontinued Products
  • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 25, 2018: Innovent receives IND approval to initiate clinical trials in china with its anti-OX40 Agonistic Antibody IBI101
      • Jul 19, 2018: Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody
      • Apr 17, 2018: Alligator Bioscience presents ATOR-1015 preclinical data at the AACR Annual Meeting 2018 confirming localized tumor activation
      • Jan 25, 2018: Alligator Bioscience contracts Theradex Oncology as clinical CRO for the forthcoming Phase I study with ATOR-1015
      • Jul 08, 2017: Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015
      • May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ATOR-1015
      • Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ATOR-1015 at PEGS conference in Boston, May 4
      • Mar 07, 2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting
      • Nov 30, 2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors
      • Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN-1949 at the American Association for Cancer Research (AACR) 2016 Annual Meeting
      • Nov 03, 2015: GSK and Merck to study immunotherapy combination as potential cancer treatment
      • Sep 21, 2011: AgonOx Receives US Patent For OX40 Ligand Fusion Proteins And Use In Cancer Therapy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research